Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Wockhardt Limited ( (IN:WOCKPHARMA) ) is now available.
Wockhardt Limited’s board has approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026. The statutory auditors, MSKC & Associates LLP, have issued an unmodified opinion, indicating that the company’s financial statements give a true and fair view in accordance with applicable Indian accounting standards.
The board also cleared an enabling proposal to raise capital through a mix of equity shares, convertible securities, and non-convertible securities via public or private offerings, including QIP or preferential allotments. This prospective fund-raising, subject to shareholder approval at the upcoming annual general meeting, positions Wockhardt to strengthen its balance sheet and support future growth or strategic initiatives.
More about Wockhardt Limited
Wockhardt Limited is an India-based pharmaceutical company listed on BSE and NSE under the symbol WOCKPHARMA. The company operates in the healthcare and life sciences sector, focusing on the development, manufacture, and sale of pharmaceutical formulations and related products for domestic and international markets.
Average Trading Volume: 41,460
Technical Sentiment Signal: Strong Buy
Current Market Cap: 226.6B INR
See more data about WOCKPHARMA stock on TipRanks’ Stock Analysis page.